PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.82%
R&D growth 5-10% suggests significant investment. Howard Marks would investigate if returns justify increased spending.
-13.19%
Negative G&A growth (overhead reduction) needs verification. Benjamin Graham would examine impact on operations.
No Data
No Data available this quarter, please select a different quarter.
-1.40%
Negative other expenses growth needs verification. Benjamin Graham would examine sustainability.
-2.45%
Negative operating expenses growth needs verification. Benjamin Graham would examine sustainability.
-2.45%
Negative total costs growth needs verification. Benjamin Graham would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
-1.40%
Negative D&A growth needs verification. Benjamin Graham would examine asset reduction strategy.
-13.13%
Negative EBITDA growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
2.45%
Operating income growth 0-4% indicates modest gains. Howard Marks would investigate growth potential.
No Data
No Data available this quarter, please select a different quarter.
49.45%
Other expenses growth above 30% signals concerning expansion. Seth Klarman would scrutinize unusual items.
10.71%
Pre-tax income growth 8-12% reflects healthy business expansion. Philip Fisher would verify competitive position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.71%
Net income growth 8-12% reflects healthy business expansion. Philip Fisher would verify competitive position.
No Data
No Data available this quarter, please select a different quarter.
23.59%
EPS growth above 15% demonstrates exceptional shareholder value creation. Warren Buffett would verify sustainability.
23.59%
Diluted EPS growth above 15% demonstrates exceptional value creation despite potential dilution. Warren Buffett would verify sustainability.
16.70%
Share increase above 2% signals significant dilution. Seth Klarman would demand explanation.
16.70%
Diluted share increase above 2% signals significant dilution. Seth Klarman would demand explanation.